<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; Robust</title>
	<atom:link href="http://www.tapanray.in/tag/robust/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Robust Patents, Not Tweaked Monopolies: India’s Practical Route to Affordable Medicines</title>
		<link>http://www.tapanray.in/robust-patents-not-tweaked-monopolies-indias-practical-route-to-affordable-medicines/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=robust-patents-not-tweaked-monopolies-indias-practical-route-to-affordable-medicines</link>
		<comments>http://www.tapanray.in/robust-patents-not-tweaked-monopolies-indias-practical-route-to-affordable-medicines/#comments</comments>
		<pubDate>Fri, 30 May 2025 00:00:36 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[advances]]></category>
		<category><![CDATA[affordable]]></category>
		<category><![CDATA[India’s Practical Route]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[monopolies]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[Patents]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Robust]]></category>
		<category><![CDATA[Safeguards]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[therapeutic]]></category>
		<category><![CDATA[Tweaked]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10902</guid>
		<description><![CDATA[In April 2025, the United States Trade Representative (USTR) released its annual Special 301 Report, once again placing India on its &#8220;Priority Watch List&#8221; for intellectual property (IP) concerns. The report highlights persistent issues, particularly in the pharmaceutical sector, citing challenges &#8230; <a href="http://www.tapanray.in/robust-patents-not-tweaked-monopolies-indias-practical-route-to-affordable-medicines/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/robust-patents-not-tweaked-monopolies-indias-practical-route-to-affordable-medicines/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>A Tipping Point For Robust Healthcare System In India</title>
		<link>http://www.tapanray.in/a-tipping-point-for-robust-healthcare-system-in-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=a-tipping-point-for-robust-healthcare-system-in-india</link>
		<comments>http://www.tapanray.in/a-tipping-point-for-robust-healthcare-system-in-india/#comments</comments>
		<pubDate>Sun, 19 Nov 2017 23:32:58 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2017]]></category>
		<category><![CDATA[ABPI]]></category>
		<category><![CDATA[accelerated]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[andrew]]></category>
		<category><![CDATA[bottom]]></category>
		<category><![CDATA[down]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[HLEG]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[National]]></category>
		<category><![CDATA[pathway]]></category>
		<category><![CDATA[point]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Robust]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Tipping]]></category>
		<category><![CDATA[top]]></category>
		<category><![CDATA[UHC]]></category>
		<category><![CDATA[UK]]></category>
		<category><![CDATA[Universal]]></category>
		<category><![CDATA[Up]]></category>
		<category><![CDATA[witty]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8558</guid>
		<description><![CDATA[“Given the popular uptake of universal health coverage reforms elsewhere in Asia, the Feb 4 elections may be a tipping point for health in India. For example, in 2012, Joko Widodo was elected Governor of Jakarta. He launched popular UHC &#8230; <a href="http://www.tapanray.in/a-tipping-point-for-robust-healthcare-system-in-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/a-tipping-point-for-robust-healthcare-system-in-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Nutraceuticals: A Major Regulatory Step That Was Long Overdue</title>
		<link>http://www.tapanray.in/nutraceuticals-a-major-regulatory-step-that-was-long-overdue/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=nutraceuticals-a-major-regulatory-step-that-was-long-overdue</link>
		<comments>http://www.tapanray.in/nutraceuticals-a-major-regulatory-step-that-was-long-overdue/#comments</comments>
		<pubDate>Mon, 21 Dec 2015 00:00:40 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2006]]></category>
		<category><![CDATA[ASSOCHAM]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Food Safety & Standards Act]]></category>
		<category><![CDATA[gazette]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[interest]]></category>
		<category><![CDATA[notification]]></category>
		<category><![CDATA[Nutraceuticals]]></category>
		<category><![CDATA[pharmacodynamics]]></category>
		<category><![CDATA[pharmacokinetics]]></category>
		<category><![CDATA[phytochemical]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[RNCOS]]></category>
		<category><![CDATA[Robust]]></category>
		<category><![CDATA[Safety]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7346</guid>
		<description><![CDATA[Currently in India the nutraceutical products segment, with surrogate or off-label therapeutic claims, is growing at a reasonable pace. Many such products are now being directly promoted to the medical profession, just like any other modern medicines, with therapeutic claims &#8230; <a href="http://www.tapanray.in/nutraceuticals-a-major-regulatory-step-that-was-long-overdue/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/nutraceuticals-a-major-regulatory-step-that-was-long-overdue/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Robust implementation of Biosimilar Guidelines could help India earn leadership status in ‘Biosimilar World’</title>
		<link>http://www.tapanray.in/robust-implementation-of-biosimilar-guidelines-could-help-india-earn-leadership-status-in-biosimilar-world/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=robust-implementation-of-biosimilar-guidelines-could-help-india-earn-leadership-status-in-biosimilar-world</link>
		<comments>http://www.tapanray.in/robust-implementation-of-biosimilar-guidelines-could-help-india-earn-leadership-status-in-biosimilar-world/#comments</comments>
		<pubDate>Mon, 05 Nov 2012 00:00:08 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[abbott]]></category>
		<category><![CDATA[biosimilar]]></category>
		<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[Compulsory Licensing]]></category>
		<category><![CDATA[could]]></category>
		<category><![CDATA[Counterfeit]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[earn]]></category>
		<category><![CDATA[Ethical Marketing]]></category>
		<category><![CDATA[FDI]]></category>
		<category><![CDATA[glaxo]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Guidelines]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[help]]></category>
		<category><![CDATA[Hospital]]></category>
		<category><![CDATA[implementation]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[kopran]]></category>
		<category><![CDATA[leadership]]></category>
		<category><![CDATA[Legal]]></category>
		<category><![CDATA[Medical Diagnostics]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[Neutraceutical]]></category>
		<category><![CDATA[NPPA]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[OPPI]]></category>
		<category><![CDATA[Patents]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[PHC]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[RDP]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[Research & Development]]></category>
		<category><![CDATA[Robust]]></category>
		<category><![CDATA[sami]]></category>
		<category><![CDATA[Spurious]]></category>
		<category><![CDATA[stakeholders]]></category>
		<category><![CDATA[status]]></category>
		<category><![CDATA[strategy]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[therapeutic]]></category>
		<category><![CDATA[Trials]]></category>
		<category><![CDATA[World]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=1072</guid>
		<description><![CDATA[Across the world, biologic drugs, in general, have a successful record in treating many life threatening and other complicated ailments. Expiration of product patents of the first major group of originators&#8217; biologic molecules has led to the development of products &#8230; <a href="http://www.tapanray.in/robust-implementation-of-biosimilar-guidelines-could-help-india-earn-leadership-status-in-biosimilar-world/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/robust-implementation-of-biosimilar-guidelines-could-help-india-earn-leadership-status-in-biosimilar-world/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Does China provide a more robust IPR environment than India?</title>
		<link>http://www.tapanray.in/does-china-provide-a-more-robust-ipr-environment-than-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=does-china-provide-a-more-robust-ipr-environment-than-india</link>
		<comments>http://www.tapanray.in/does-china-provide-a-more-robust-ipr-environment-than-india/#comments</comments>
		<pubDate>Mon, 08 Nov 2010 01:00:09 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[a]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[dispute]]></category>
		<category><![CDATA[Does]]></category>
		<category><![CDATA[environment]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[infringement]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[linkage]]></category>
		<category><![CDATA[more]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[Protection]]></category>
		<category><![CDATA[provide]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[RDP]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[Robust]]></category>
		<category><![CDATA[settlement]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[than]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=351</guid>
		<description><![CDATA[Soon after the Product Patent Act was reintroduced in India effective January 1, 2005, a raging global debate commenced focusing on the robustness of the Indian Patent system. Quite often, many participants in the debate continue to compare the adequacies &#8230; <a href="http://www.tapanray.in/does-china-provide-a-more-robust-ipr-environment-than-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/does-china-provide-a-more-robust-ipr-environment-than-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Creating an IPR friendly robust ‘Echo-System’ and &#8216;Improving Access to Affordable Medicines&#8217; are not either/or situation in India</title>
		<link>http://www.tapanray.in/creating-an-ipr-friendly-robust-echo-system-and-improving-access-to-affordable-medicines-are-not-eitheror-situation-in-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=creating-an-ipr-friendly-robust-echo-system-and-improving-access-to-affordable-medicines-are-not-eitheror-situation-in-india</link>
		<comments>http://www.tapanray.in/creating-an-ipr-friendly-robust-echo-system-and-improving-access-to-affordable-medicines-are-not-eitheror-situation-in-india/#comments</comments>
		<pubDate>Mon, 13 Sep 2010 01:00:11 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[affordable]]></category>
		<category><![CDATA[and]]></category>
		<category><![CDATA[are]]></category>
		<category><![CDATA[Eco-System]]></category>
		<category><![CDATA[either/or]]></category>
		<category><![CDATA[friendly]]></category>
		<category><![CDATA[Improving]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovative]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[Not]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Robust]]></category>
		<category><![CDATA[situation]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[to]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=375</guid>
		<description><![CDATA[Last year, though the growth of the Global Pharmaceutical Industry with a turnover of US$ 752 billion significantly slowed down to just 6.7% due to various contributing factors, the Indian Pharmaceutical Industry continued to maintain a robust of growth of &#8230; <a href="http://www.tapanray.in/creating-an-ipr-friendly-robust-echo-system-and-improving-access-to-affordable-medicines-are-not-eitheror-situation-in-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/creating-an-ipr-friendly-robust-echo-system-and-improving-access-to-affordable-medicines-are-not-eitheror-situation-in-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>To avoid “Heparin” like tragedy in future, a robust “supply chain integrity and security” system is of critical importance</title>
		<link>http://www.tapanray.in/to-avoid-heparin-like-tragedy-in-future-a-robust-supply-chain-integrity-and-security-system-is-of-critical-importance/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=to-avoid-heparin-like-tragedy-in-future-a-robust-supply-chain-integrity-and-security-system-is-of-critical-importance</link>
		<comments>http://www.tapanray.in/to-avoid-heparin-like-tragedy-in-future-a-robust-supply-chain-integrity-and-security-system-is-of-critical-importance/#comments</comments>
		<pubDate>Mon, 29 Mar 2010 00:30:14 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[a]]></category>
		<category><![CDATA[and]]></category>
		<category><![CDATA[avoid]]></category>
		<category><![CDATA[chain]]></category>
		<category><![CDATA[critical]]></category>
		<category><![CDATA[future]]></category>
		<category><![CDATA[Heparin]]></category>
		<category><![CDATA[importance]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[Integrity]]></category>
		<category><![CDATA[is]]></category>
		<category><![CDATA[like]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Robust]]></category>
		<category><![CDATA[SCM]]></category>
		<category><![CDATA[SCS]]></category>
		<category><![CDATA[Security]]></category>
		<category><![CDATA[Supply]]></category>
		<category><![CDATA[system]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[to]]></category>
		<category><![CDATA[tragedy]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=448</guid>
		<description><![CDATA[Globally the pharmaceutical industry is going through a metamorphosis. The types of changes that are taking place today globally, perhaps has no precedence.. The key drivers of these changes are mainly the following: 1. A large number of patent expiration &#8230; <a href="http://www.tapanray.in/to-avoid-heparin-like-tragedy-in-future-a-robust-supply-chain-integrity-and-security-system-is-of-critical-importance/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/to-avoid-heparin-like-tragedy-in-future-a-robust-supply-chain-integrity-and-security-system-is-of-critical-importance/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Emerging markets and a robust oncology portfolio expected to be the future growth engine of the global pharmaceutical industry&#8230; but not without associated pricing pressures.</title>
		<link>http://www.tapanray.in/emerging-markets-and-a-robust-oncology-portfolio-expected-to-be-the-future-growth-engine-of-the-global-pharmaceutical-industry-but-not-without-associated-pricing-pressures/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=emerging-markets-and-a-robust-oncology-portfolio-expected-to-be-the-future-growth-engine-of-the-global-pharmaceutical-industry-but-not-without-associated-pricing-pressures</link>
		<comments>http://www.tapanray.in/emerging-markets-and-a-robust-oncology-portfolio-expected-to-be-the-future-growth-engine-of-the-global-pharmaceutical-industry-but-not-without-associated-pricing-pressures/#comments</comments>
		<pubDate>Thu, 08 Oct 2009 01:00:56 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[a]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[Affordability]]></category>
		<category><![CDATA[and]]></category>
		<category><![CDATA[associated]]></category>
		<category><![CDATA[be]]></category>
		<category><![CDATA[But]]></category>
		<category><![CDATA[cliff]]></category>
		<category><![CDATA[containment]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[emerging]]></category>
		<category><![CDATA[engine]]></category>
		<category><![CDATA[expected]]></category>
		<category><![CDATA[future]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[growth]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[markets]]></category>
		<category><![CDATA[Not]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[oncology]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[portfolio]]></category>
		<category><![CDATA[pressures]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[productivity]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Robust]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[to]]></category>
		<category><![CDATA[UK]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[without]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=760</guid>
		<description><![CDATA[When the growth rate of the developed markets of the global pharmaceutical industry started slowing down along with the declining R&#38;D productivity, the emerging markets were identified as the new ‘El-Dorado’ by the global players. At the same time, new &#8230; <a href="http://www.tapanray.in/emerging-markets-and-a-robust-oncology-portfolio-expected-to-be-the-future-growth-engine-of-the-global-pharmaceutical-industry-but-not-without-associated-pricing-pressures/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/emerging-markets-and-a-robust-oncology-portfolio-expected-to-be-the-future-growth-engine-of-the-global-pharmaceutical-industry-but-not-without-associated-pricing-pressures/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>How to have a robust product patent enforcement mechanism, without getting involved into expensive litigations, frequently?</title>
		<link>http://www.tapanray.in/how-to-have-a-robust-product-patent-enforcement-mechanism-without-getting-involved-into-expensive-litigations-frequently/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=how-to-have-a-robust-product-patent-enforcement-mechanism-without-getting-involved-into-expensive-litigations-frequently</link>
		<comments>http://www.tapanray.in/how-to-have-a-robust-product-patent-enforcement-mechanism-without-getting-involved-into-expensive-litigations-frequently/#comments</comments>
		<pubDate>Thu, 03 Sep 2009 01:30:41 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[enforcement]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[mechanism]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Product]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Robust]]></category>
		<category><![CDATA[Tapan]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=789</guid>
		<description><![CDATA[On August 28, 2009, the Supreme Court of India dismissed the special leave petition filed by Roche challenging the order of the division bench of the Delhi High Court. Earlier the division bench had refused to grant an interim relief &#8230; <a href="http://www.tapanray.in/how-to-have-a-robust-product-patent-enforcement-mechanism-without-getting-involved-into-expensive-litigations-frequently/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/how-to-have-a-robust-product-patent-enforcement-mechanism-without-getting-involved-into-expensive-litigations-frequently/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
